Summary video

Summary video: Exploring the unmet need in metastatic prostate cancer

The incidence of metastatic prostate cancer is rising

The rising incidence of metastatic prostate cancer with more aggressive, high-risk subtypes requires further advancements in patient care.5–8

~40%

Increase in the US incidence of metastatic prostate cancer from 2011 to 20185

5–10%

Proportion of prostate cancers globally diagnosed as de novo mHSPC, an aggressive, high-risk subtype8,9

2.9
million

Expected new annual cases of prostate cancer worldwide by 204010

Incidence facts and figures

Explore the incidence of metastatic prostate cancer and share with your network.

View infographic (PDF)
Incidence of Metastatic Prostate Cancer in the US

Despite treatment advances, disease progression from mHSPC to mCRPC still occurs, with poor survival rates1,2

Know the numbers

1
year

Median time to progression from mHSPC to mCRPC11

2–3
years

Median survival of a patient once they develop mCRPC2,12

50%

Proportion of prostate cancer-related deaths caused by de novo mHSPC8

35%

5-year overall survival for patients with de novo mHSPC13

45%

Proportion of patients with mHSPC in the US undertreated with ADT monotherapy3

Progression from mHSPC to mCRPC may be related to biomarker-driven mechanisms of resistance4,14

Despite metastatic prostate cancer treatment advances with current doublet and triplet combination strategies, outcomes for patients with aggressive, high-risk forms of mHSPC remain poor.13

Therapeutic strategies targeting underlying biomarker-driven mechanisms of resistance are needed for early treatment of these patients, to potentially help delay progression to mCRPC and prolong survival.3,4

knowledge check

ADT, androgen deprivation therapy; AKT, protein kinase B; mCRPC, metastatic castration-resistant prostate cancer; mHSPC, metastatic hormone-sensitive prostate cancer; PI3K, phosphoinositide 3-kinase; PTEN, phosphatase and tensin homolog.

1. Ng K, et al. Oncol Ther. 2020;8(2):209–230; 2. Freedland SJ, et al. Prostate Cancer Prostatic Dis. 2024;27(2):327–333; 3. Ryan CJ, et al. J Urol. 2021;206(6):1420–1429; 4. Zhang JY, et al. Asian J Androl. 2022;24(1):50–55; 5. Desai MM, et al. JAMA Netw Open. 2022;5(3):e222246; 6. Weiner AB, et al. Prostate Cancer Prostatic Dis. 2016;19(4):395–397; 7. Hu JC, et al. JAMA Oncol. 2017;3(5):705–707; 8. Piombino C, et al. Cancers. 2023;15(20):4945; 9. Helgstrand JT, et al. Cancer. 2018;124(14):2931–2938; 10. James ND, et al. Lancet. 2024;403(10437):1683–1722; 11. Svensson J, et al. Scand J Urol. 2021;55(1):1–8; 12. Moreira DM, et al. Clin Genitourin Cancer. 2017;15(1):60–66; 13. Corsini C, et al. JAMA Netw Open. 2023;6(10):e2336604; 14. Jamaspishvili T, et al. Nat Rev Urol. 2018;15(4):222–234.